BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37054895)

  • 1. Internal and external modulation factors of the orexin system (REVIEW).
    Maruyama T; Ueta Y
    Peptides; 2023 Jul; 165():171009. PubMed ID: 37054895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptides controlling energy balance: orexins and neuromedins.
    Nixon JP; Kotz CM; Novak CM; Billington CJ; Teske JA
    Handb Exp Pharmacol; 2012; (209):77-109. PubMed ID: 22249811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orexins: effects on behavior and localisation of orexin receptor 2 messenger ribonucleic acid in the rat brainstem.
    Sunter D; Morgan I; Edwards CM; Dakin CL; Murphy KG; Gardiner J; Taheri S; Rayes E; Bloom SR
    Brain Res; 2001 Jul; 907(1-2):27-34. PubMed ID: 11430882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the orexin (hypocretin) system in controlling energy homeostasis, endocrine system, and reproduction in pigs and other living organisms.
    Wojciechowicz T; Rybska M; Smolinska N; Kaminski T; Rak A; Wlodarek J; Nowak KW; Skrzypski M
    J Physiol Pharmacol; 2023 Dec; 74(6):. PubMed ID: 38345440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
    Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
    Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
    Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
    PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diurnal Regulation of the Orexin/Hypocretin System in Mice.
    Ventzke K; Oster H; Jöhren O
    Neuroscience; 2019 Nov; 421():59-68. PubMed ID: 31678347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular Localization of Orexin 1 Receptor in Human Hypothalamus and Morphological Analysis of Neurons Expressing the Receptor.
    Vraka K; Mytilinaios D; Katsenos AP; Serbis A; Baloyiannis S; Bellos S; Simos YV; Tzavellas NP; Konitsiotis S; Vezyraki P; Peschos D; Tsamis KI
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole Brain Mapping of Orexin Receptor mRNA Expression Visualized by Branched In Situ Hybridization Chain Reaction.
    Tsuneoka Y; Funato H
    eNeuro; 2024 Feb; 11(2):. PubMed ID: 38199807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin/hypocretin.
    Inutsuka A; Yamanaka A
    Nagoya J Med Sci; 2013 Feb; 75(1-2):29-36. PubMed ID: 23544265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
    Sun Y; Tisdale RK; Kilduff TS
    Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Synthesis of Orexin 1 Receptor-Selective Agonists.
    Iio K; Hashimoto K; Nagumo Y; Amezawa M; Hasegawa T; Yamamoto N; Kutsumura N; Takeuchi K; Ishikawa Y; Yamamoto H; Tokuda A; Sato T; Uchida Y; Inoue A; Tanimura R; Yanagisawa M; Nagase H; Saitoh T
    J Med Chem; 2023 Apr; 66(8):5453-5464. PubMed ID: 37043436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippocampal orexin receptors: Localization and function.
    Elahdadi Salmani M; Sarfi M; Goudarzi I
    Vitam Horm; 2022; 118():393-421. PubMed ID: 35180935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies.
    Ten-Blanco M; Flores Á; Cristino L; Pereda-Pérez I; Berrendero F
    Front Neuroendocrinol; 2023 Apr; 69():101066. PubMed ID: 37015302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression and protein distribution of orexins and orexin receptors in rat retina.
    Liu F; Xu GZ; Wang L; Jiang SX; Yang XL; Zhong YM
    Neuroscience; 2011 Aug; 189():146-55. PubMed ID: 21621592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent trends in orexin research--2010 to 2015.
    Boss C; Roch C
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2875-87. PubMed ID: 26045032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of estrone and estradiol on the expression of the orexin/hypocretin system in the porcine uterus during early pregnancy.
    Kiezun M; Dobrzyn K; Rytelewska E; Kisielewska K; Gudelska M; Szeszko K; Zaobidna E; Bors K; Wyrebek J; Mykytiuk A; Kaminski T; Smolinska N
    Domest Anim Endocrinol; 2019 Jul; 68():11-24. PubMed ID: 30784944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orexins and gastrointestinal functions.
    Baccari MC
    Curr Protein Pept Sci; 2010 Mar; 11(2):148-55. PubMed ID: 20353399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocretin/orexin and energy expenditure.
    Teske JA; Billington CJ; Kotz CM
    Acta Physiol (Oxf); 2010 Mar; 198(3):303-12. PubMed ID: 20070282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.